Dana-Farber Cancer Institute | Strategic Alliance Partners

December 16, 2017

Matthew S. Davids, MD, MMSc, Associate Director, Dana-Farber Cancer Institute, Center for Chronic Lymphocytic Leukemia, discusses ibrutinib plus FCR in younger patients with CLL.

December 14, 2017

Tari King, MD, FACS, chief of Breast Surgery, Dana-Farber Cancer Institute, Brigham Women’s Cancer Center, discusses lymph node resection in breast cancer.

November 15, 2017

Richard M. Stone, MD, director of the Adult Leukemia Program, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses monitoring patients with acute myeloid leukemia.

November 14, 2017

Guru P. Sonpavde, MD, discusses degarelix, androgen-deprivation therapy, and ongoing trials with immunotherapy that are crucial to advancing the treatment of patients with prostate cancer.

October 25, 2017

Rachel A. Freedman, MD, discusses treating patients with HER2-positive breast cancer who develop CNS metastases, and the promise that neratinib holds in this patient population.

September 21, 2017

Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses the rationale behind combining VEGF-targeted therapies and radium-223 dichloride (Xofigo) in metastatic renal cell carcinoma.

September 19, 2017

Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, instructor of medicine, Harvard Medical School, discusses the future of treatment for renal cell carcinoma.

September 08, 2017

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses pertuzumab (Perjeta) in patients with HER2-positive breast cancer.

September 06, 2017

In an ongoing phase II trial, researchers are investigating several targeted agents for use in the treatment of patients with glioblastoma (GBM).

June 29, 2017

Rachel A. Freedman, MD, MPH, associate clinical director, Breast Oncology Center, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, senior physician, assistant professor of medicine, Harvard Medical School, discusses dual HER2-targeted therapies in breast cancer.

June 27, 2017

Jennifer Ligibel, MD, describes the BWEL trial and the possible impact of weight loss intervention for patients with breast cancer.

June 13, 2017

Researchers at Dana-Farber Cancer Institute and Brigham and Women’s Hospital are attempting to improve personalized medicine by analyzing DNA samples for known cancer biomarkers.

May 31, 2017

Anna Farago, MD, PhD, Massachusetts General Hospital Cancer Center, instructor of Medicine at Harvard Medical School, discusses opportunities for the development of biomarkers for patients with small cell lung cancer (SCLC).

May 30, 2017

Results from the KEYNOTE-028 study showed that pembrolizumab (Keytruda) was associated with a median duration of response of 6 months and a 6-month progression-free survival rate of 40.4% in women with advanced PD-L1–positive endometrial cancer.

May 23, 2017

Ursula A. Matulonis, MD, professor of Medicine, Harvard Medical School, medical director of Gynecologic Oncology, Dana-Farber Cancer Institute, discusses toxicities associated with PARP inhibitors in ovarian cancer.

May 03, 2017

Matthew B. Yurgelun, MD, assistant professor of Medicine, Harvard Medical School, and a researcher at the Dana-Farber Cancer Institute, discusses germline testing in colorectal cancer.

May 02, 2017

Suzanne George, MD, assistant professor of Medicine, Harvard Medical School, clinical director, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, discusses a study exploring the efficacy of a PD-1 inhibitor in patients with uterine leiomyosarcoma.

April 26, 2017

Ursula A. Matulonis, MD, professor of Medicine, Harvard Medical School, medical director of Gynecologic Oncology, Dana-Farber Cancer Institute, discusses maintenance therapy in ovarian cancer.

April 24, 2017

Suzanne George, MD, discusses an exceptional responder to pembrolizumab in leiomyosarcoma and the significance of these findings for further immunotherapy advances in the field.

April 24, 2017

Anna Farago, MD, PhD, assistant, Medicine, Massachusetts General Hospital Cancer Center, and instructor, Medicine, at Harvard Medical School, discusses the combination of olarparib (Lynparza) and temozolomide (Temodar) for patients with small cell lung cancer (SCLC).